Peptides by condition · Heart, kidneys and lungs
Peptides studied for heart disease
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 17 study pages on heart disease: 12 in people (11 of them meta-analyses or randomized trials), and 5 in animals. They studied 14 compounds, with this many study pages each: Semaglutide 2, Semaglutide (oral) 2, SS-31 2, Exenatide 1, Dulaglutide 1, Liraglutide 1, Orforglipron 1, NAD+ 1, Thymosin Beta-4 1, Ac-SDKP 1, BPC-157 1, Hexarelin 1, PEG-MGF 1 and SLU-PP-332 1.
What the research on heart disease looks like
Heart disease covers narrowed heart arteries, heart attacks, heart failure and irregular rhythms. The peptide studies on it come in two kinds: large trials that followed people with diabetes or excess weight for years and counted heart attacks, strokes and heart deaths, and smaller studies that gave a peptide around a heart attack to see whether it limited the damage.
The large trials count a combined outcome, usually death from heart causes, a nonfatal heart attack or a nonfatal stroke, and report it as a hazard ratio against placebo. The heart attack studies measure the size of the damaged area on a scan.
A trial that only shows a drug is no worse for the heart than placebo answers a safety question, not whether it lowers risk, so read which question a trial was built to answer. Results in rat or mouse hearts are early.

The 17 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Semaglutide
2 in peopleFor heart disease, 2 of our study pages are filed under Semaglutide: 2 randomized trials in people. The largest in people enrolled 17,604 people and was published in 2023. They were published from 2016 to 2023, in N Engl J Med.
FDA-approved, with a use tied to heart disease on its label: Ozempic (injection) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack, stroke and kidney decline in those with heart or kidney disease; Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Wegovy (injection) for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and a fatty-liver disease (MASH) with moderate to advanced scarring; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus).
- Randomized trial in people · 17,604 people · 2023Semaglutide: 6.5% vs 8.0% had a major heart event in SELECT
- Randomized trial in people · 3,297 people · 2016Semaglutide: 6.6% vs 8.9% heart or stroke events in SUSTAIN-6
Semaglutide (oral)
2 in peopleFor heart disease, 2 of our study pages are filed under Semaglutide (oral): 2 randomized trials in people. The largest in people enrolled 9,650 people and was published in 2025. They were published from 2019 to 2025, in N Engl J Med.
FDA-approved, with a use tied to heart disease on its label: Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus).
- Randomized trial in people · 9,650 people · 2025Semaglutide (oral): fewer major heart events than placebo in SOUL
- Randomized trial in people · 3,183 people · 2019Semaglutide (oral): heart risk not higher than placebo in PIONEER 6
SS-31
2 in peopleFor heart disease, 2 of our study pages are filed under SS-31: 1 randomized trial and 1 clinical trial in people. Its studies in people do not give their size on our pages. They were published from 2016 to 2019, in Eur Heart J and Eur Heart J Acute Cardiovasc Care.
FDA-approved for other uses, not for heart disease: Forzinity (injection) for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg (an accelerated approval; it may depend on a confirmatory trial).
- Randomized trial in people · 2016SS-31 did not significantly cut infarct size in EMBRACE STEMI
- Clinical trial in people · 2019SS-31 (elamipretide) lowered blood HtrA2 after STEMI heart attack
Exenatide
1 in peopleFor heart disease, 1 of our study pages is filed under Exenatide: 1 randomized trial in people. It enrolled 14,752 people and was published in 2017, in N Engl J Med.
FDA-approved for other uses, not for heart disease: Byetta (injection) for blood sugar control, with diet and exercise, in adults with type 2 diabetes.
- Randomized trial in people · 14,752 people · 2017Exenatide: no significant drop in heart events vs placebo in EXSCEL
Dulaglutide
1 in peopleFor heart disease, 1 of our study pages is filed under Dulaglutide: 1 randomized trial in people. It enrolled 9,901 people and was published in 2019, in Lancet.
FDA-approved, with a use tied to heart disease on its label: Trulicity (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease or several heart risk factors.
- Randomized trial in people · 9,901 people · 2019Dulaglutide lowered major cardiovascular events (HR 0.88) in REWIND
Liraglutide
1 in peopleFor heart disease, 1 of our study pages is filed under Liraglutide: 1 randomized trial in people. It enrolled 9,340 people and was published in 2016, in N Engl J Med.
FDA-approved, with a use tied to heart disease on its label: Victoza (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease. Under Saxenda it is approved for other uses.
- Randomized trial in people · 9,340 people · 2016Liraglutide: 13.0% vs 14.9% major cardiovascular events in LEADER
Orforglipron
1 in peopleFor heart disease, 1 of our study pages is filed under Orforglipron: 1 randomized trial in people. It enrolled 2,749 people and was published in 2026, in Lancet.
FDA-approved for other uses, not for heart disease: Foundayo (tablet) for weight loss and keeping it off, in adults with obesity or with excess weight and a weight-related condition.
- Randomized trial in people · 2,749 people · 2026Orforglipron: heart events no worse than insulin in ACHIEVE-4
NAD+
1 in peopleFor heart disease, 1 of our study pages is filed under NAD+: 1 randomized trial in people. It enrolled 180 people and was published in 2026, in Am J Cardiovasc Drugs.
NAD+ has no FDA-approved drug: Drugs@FDA lists no application for it.
- Randomized trial in people · 180 people · 2026NAD+ improved LVEF at 1 month in ischemic heart failure
Thymosin Beta-4
1 in peopleFor heart disease, 1 of our study pages is filed under Thymosin Beta-4: 1 randomized trial in people. It enrolled 96 people and was published in 2025, in Cardiovasc Res.
Thymosin beta-4 has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 96 people · 2025Thymosin beta-4: no overall infarct area cut in 96 STEMI patients
Ac-SDKP
1 in animalsFor heart disease, 1 of our study pages is filed under Ac-SDKP: 1 animal study (mice). It was published in 2019, in Can J Physiol Pharmacol.
Ac-SDKP has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2019Ac-SDKP cut heart rupture and aided heart function in mice after MI
BPC-157
1 in animalsFor heart disease, 1 of our study pages is filed under BPC-157: 1 animal study (rats). It was published in 2022, in Biomedicines.
BPC-157 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in rats · 2022BPC-157 limited isoprenaline-induced heart attack damage in rats
Hexarelin
1 in animalsFor heart disease, 1 of our study pages is filed under Hexarelin: 1 animal study (rats). It was published in 1999, in Endocrinology.
Hexarelin (examorelin) has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in rats · 1999Hexarelin protected rat hearts from ischemia-reperfusion damage
PEG-MGF
1 in animalsFor heart disease, 1 of our study pages is filed under PEG-MGF: 1 animal study (mice). It was published in 2013, in Mol Cell Biochem.
PEG-MGF has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2013PEG-MGF: heart function preserved after heart attack in mice
SLU-PP-332
1 in animalsFor heart disease, 1 of our study pages is filed under SLU-PP-332: 1 animal study (mice). It was published in 2024, in Circulation.
SLU-PP-332 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2024SLU-PP-332 improved ejection fraction and survival in mice
Side by side
For the 14 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Semaglutide | 2 | 0 | 17,604 | Approved, a use tied to it |
| Semaglutide (oral) | 2 | 0 | 9,650 | Approved, a use tied to it |
| SS-31 | 2 | 0 | — | Approved for other uses |
| Exenatide | 1 | 0 | 14,752 | Approved for other uses |
| Dulaglutide | 1 | 0 | 9,901 | Approved, a use tied to it |
| Liraglutide | 1 | 0 | 9,340 | Approved, a use tied to it |
| Orforglipron | 1 | 0 | 2,749 | Approved for other uses |
| NAD+ | 1 | 0 | 180 | Not approved |
| Thymosin Beta-4 | 1 | 0 | 96 | Not approved |
| Ac-SDKP | 0 | 1 | — | Not approved |
| BPC-157 | 0 | 1 | — | Not approved |
| Hexarelin | 0 | 1 | — | Not approved |
| PEG-MGF | 0 | 1 | — | Not approved |
| SLU-PP-332 | 0 | 1 | — | Not approved |
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 17,604
- FDA
- Approved, a use tied to it
- In people
- 2
- Animals or cells
- 0
- Largest in people
- 9,650
- FDA
- Approved, a use tied to it
- In people
- 2
- Animals or cells
- 0
- Largest in people
- —
- FDA
- Approved for other uses
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 14,752
- FDA
- Approved for other uses
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 9,901
- FDA
- Approved, a use tied to it
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 9,340
- FDA
- Approved, a use tied to it
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 2,749
- FDA
- Approved for other uses
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 180
- FDA
- Not approved
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 96
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Semaglutide: 6.5% vs 8.0% had a major heart event in SELECTIt included only people aged 45 or older who already had heart disease, so it does not show the effect in people without heart disease or in people with diabetes. It tested one dose, and the trial was funded by Novo Nordisk.
- Semaglutide (oral): fewer major heart events than placebo in SOULThe trial only included people aged 50 or older with type 2 diabetes plus artery or kidney disease, so it does not show the same effect in people without diabetes or at lower risk, and it found no significant kidney benefit. It was funded by Novo Nordisk.
- SS-31 did not significantly cut infarct size in EMBRACE STEMIThis was a mid-stage Phase 2a trial limited to first-time anterior heart attacks from an LAD blockage, so it does not show how other heart attack patients would respond. It tested a single 1-hour infusion at one dose rate and does not show what longer or different dosing would do.
- Exenatide: no significant drop in heart events vs placebo in EXSCELThe trial tested only the 2 mg once-weekly form in people with type 2 diabetes, so it does not speak to other doses or to people without diabetes. It was funded by Amylin Pharmaceuticals.
- Dulaglutide lowered major cardiovascular events (HR 0.88) in REWINDOnly one dose, 1.5 mg weekly, was tested, and only in people aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors. The trial was funded by Eli Lilly and Company.
- Liraglutide: 13.0% vs 14.9% major cardiovascular events in LEADERThe trial only enrolled people with type 2 diabetes at high cardiovascular risk, and the prespecified exploratory outcomes were not adjusted for testing many outcomes at once. It was funded by Novo Nordisk and the National Institutes of Health.
- Thymosin Beta-4: Thymosin beta-4: no overall infarct area cut in 96 STEMI patientsThe human trial missed its overall comparison, and the positive result comes from a subgroup defined by dosing time. The heart function, scarring and cell results come from mice and lab-grown cells, not people.
- BPC-157 limited isoprenaline-induced heart attack damage in ratsThis was done in rats with heart damage brought on by a drug, so it is not a human result. Effects were followed only over short periods, up to about 24 hours after the last isoprenaline dose.
- PEG-MGF: heart function preserved after heart attack in miceEvery result here comes from H9c2 cells and mice, so none of it has been shown in people. Mice were checked at only 2 weeks after the heart attack, and the substance given was a synthetic copy of the MGF E-domain region.
- SLU-PP-332 improved ejection fraction and survival in miceThis was work in mice and cells, so it does not show what SLU-PP-332 does in people with heart failure. It tested one type of heart failure model.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for heart disease?
Our 17 study pages on heart disease are filed under 14 compounds, with this many each: Semaglutide 2, Semaglutide (oral) 2, SS-31 2, Exenatide 1, Dulaglutide 1, Liraglutide 1, Orforglipron 1, NAD+ 1, Thymosin Beta-4 1, Ac-SDKP 1, BPC-157 1, Hexarelin 1, PEG-MGF 1 and SLU-PP-332 1. Semaglutide, Semaglutide (oral) and SS-31 have the most, 2 each.
Have any been tested in people with heart disease?
Yes: 12 of the 17 were in people, 11 of them meta-analyses or randomized trials (Semaglutide, Semaglutide (oral), SS-31, Exenatide, Dulaglutide, Liraglutide, Orforglipron, NAD+ and Thymosin Beta-4). The largest enrolled 17,604 people: “Semaglutide: 6.5% vs 8.0% had a major heart event in SELECT” (2023).
Is any peptide FDA-approved for heart disease?
Yes, with a use tied to heart disease on their FDA labels: Semaglutide as Ozempic, Rybelsus and Wegovy; Semaglutide (oral) as Rybelsus, Wegovy and Ozempic; Dulaglutide as Trulicity; Liraglutide as Victoza. 10 other compounds here with an FDA record have no use tied to it.
How large were the studies in people on heart disease?
Of the 12 in people, 10 give their size on our pages: 8 had 1,000 people or more, 1 had 100 to 999 and 1 had fewer than 100. The largest, a randomized trial from 2023, enrolled 17,604.
What did the animal and cell studies on heart disease use?
5 animal studies (mice and rats), filed under SLU-PP-332, BPC-157, Ac-SDKP, PEG-MGF and Hexarelin. A result in animals or cells shows what to test next, not what happens in a person.
What is the newest study on heart disease here?
Of our study pages on heart disease, the newest is “Orforglipron: heart events no worse than insulin in ACHIEVE-4”, a randomized trial in people published in 2026.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.